Global Carrier Screening Market

Carrier Screening Comprehensive Study by Type (Molecular Screening Test, Biochemical Screening Test), Application (Hospitals, Clinics, Ambulatory Surgical Centers), Medical Conditions (Fragile x syndrome, Spinal muscular atrophy, Alpha thalassemia, Cystic fibrosis), Solution (Service, Product) Players and Region - Global Market Outlook to 2028

Carrier Screening Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Carrier Screening Market?

Carrier screening is a type of genetic test used to determine if a healthy person is a carrier of a recessive genetic disease. These persons display no symptoms of a genetic disorder but may be at risk of passing it on to their children. Carrier screening test provides life-lasting information about an individual's reproductive risk and their chances of having a child with a genetic disease. There are two types of this test including molecular testing and biochemical testing. Molecular testing analyzes the DNA-genetic code and biochemical testing measures enzyme activity.

Highlights from Carrier Screening Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAbbott Laboratories (United States), Roche Holding AG (Switzerland), Thermo Fisher Scientific (United States), 23andMe (United States), Danaher Corporation (United States), QIAGEN (Germany), Illumina, Inc. (United States), Luminex Corporation (United States), LabCorp (United States), Myriad Genetics, Inc. (United States) and Autogenomics (United States)


Manufacturers focus on technological advancements to streamline the carrier screening process. This can include automation of laboratory processes, integration with electronic medical record systems, and efficient sample collection methods. Utilize cutting-edge technologies to improve turnaround time, reduce costs, and enhance the overall user experience. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Carrier Screening market throughout the forecasted period.

Abbott Laboratories (United States), Roche Holding AG (Switzerland), Thermo Fisher Scientific (United States), 23andMe (United States), Danaher Corporation (United States), QIAGEN (Germany), Illumina, Inc. (United States), Luminex Corporation (United States), LabCorp (United States), Myriad Genetics, Inc. (United States) and Autogenomics (United States) are some of the key players profiled in the study.

Carrier Screening Market Segmentation:
ScopeSub-Segments
Application / End UserHospitals, Clinics and Ambulatory Surgical Centers
TypeMolecular Screening Test and Biochemical Screening Test
Medical ConditionsFragile x syndrome,Spinal muscular atrophy,Alpha thalassemia,Cystic fibrosis
SolutionService,Product


On the basis of geography, the market of Carrier Screening has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Focus on Preventive Healthcare

Market Growth Drivers:
Increased Prevalence of Genetic Disorders and Technological Advancements in the Medical Science

Challenges:
Lack of Skilled Professionals

Restraints:
Stringent Regulations for the Approval of Carrier Screening Tests

Opportunities:
Growing Healthcare Infrastructure in Developing Regions, Increasing Number of Hospitals and Clinics and Rising Awareness among People about Healthy Lifestyle

Key Target Audience
Carrier Screening Testing Providers, Emerging Companies, Research Professionals, End-users and Others

Market Leaders & Development Strategies
In February 2019, Roche and Spark Therapeutics, Inc. announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics. Spark Therapeutics is a leader in discovering, developing, and delivering gene therapies with one commercial asset and four programs currently in clinical trials.
In August 2022, QIAGEN announced the expansion of its next-generation sequencing (NGS) portfolio with the launch of QIAseq Targeted DNA Pro Panels and the QIAseq UPXome RNA Library Kit, both of which set new standards in preparing samples for determining their nucleic acid sequences.


Report Objectives / Segmentation Covered

By Type
  • Molecular Screening Test
  • Biochemical Screening Test
By Application
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
By Medical Conditions
  • Fragile x syndrome
  • Spinal muscular atrophy
  • Alpha thalassemia
  • Cystic fibrosis

By Solution
  • Service
  • Product

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Genetic Disorders
      • 3.2.2. Technological Advancements in the Medical Science
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professionals
    • 3.4. Market Trends
      • 3.4.1. Growing Focus on Preventive Healthcare
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Carrier Screening, by Type, Application, Medical Conditions, Solution and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Carrier Screening (Value)
      • 5.2.1. Global Carrier Screening by: Type (Value)
        • 5.2.1.1. Molecular Screening Test
        • 5.2.1.2. Biochemical Screening Test
      • 5.2.2. Global Carrier Screening by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centers
      • 5.2.3. Global Carrier Screening by: Medical Conditions (Value)
        • 5.2.3.1. Fragile x syndrome
        • 5.2.3.2. Spinal muscular atrophy
        • 5.2.3.3. Alpha thalassemia
        • 5.2.3.4. Cystic fibrosis
      • 5.2.4. Global Carrier Screening by: Solution (Value)
        • 5.2.4.1. Service
        • 5.2.4.2. Product
      • 5.2.5. Global Carrier Screening Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Carrier Screening: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Holding AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. 23andMe (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Danaher Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. QIAGEN (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Illumina, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Luminex Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. LabCorp (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Myriad Genetics, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Autogenomics (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Carrier Screening Sale, by Type, Application, Medical Conditions, Solution and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Carrier Screening (Value)
      • 7.2.1. Global Carrier Screening by: Type (Value)
        • 7.2.1.1. Molecular Screening Test
        • 7.2.1.2. Biochemical Screening Test
      • 7.2.2. Global Carrier Screening by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centers
      • 7.2.3. Global Carrier Screening by: Medical Conditions (Value)
        • 7.2.3.1. Fragile x syndrome
        • 7.2.3.2. Spinal muscular atrophy
        • 7.2.3.3. Alpha thalassemia
        • 7.2.3.4. Cystic fibrosis
      • 7.2.4. Global Carrier Screening by: Solution (Value)
        • 7.2.4.1. Service
        • 7.2.4.2. Product
      • 7.2.5. Global Carrier Screening Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Carrier Screening: by Type(USD Million)
  • Table 2. Carrier Screening Molecular Screening Test , by Region USD Million (2017-2022)
  • Table 3. Carrier Screening Biochemical Screening Test , by Region USD Million (2017-2022)
  • Table 4. Carrier Screening: by Application(USD Million)
  • Table 5. Carrier Screening Hospitals , by Region USD Million (2017-2022)
  • Table 6. Carrier Screening Clinics , by Region USD Million (2017-2022)
  • Table 7. Carrier Screening Ambulatory Surgical Centers , by Region USD Million (2017-2022)
  • Table 8. Carrier Screening: by Medical Conditions(USD Million)
  • Table 9. Carrier Screening Fragile x syndrome , by Region USD Million (2017-2022)
  • Table 10. Carrier Screening Spinal muscular atrophy , by Region USD Million (2017-2022)
  • Table 11. Carrier Screening Alpha thalassemia , by Region USD Million (2017-2022)
  • Table 12. Carrier Screening Cystic fibrosis , by Region USD Million (2017-2022)
  • Table 13. Carrier Screening: by Solution(USD Million)
  • Table 14. Carrier Screening Service , by Region USD Million (2017-2022)
  • Table 15. Carrier Screening Product , by Region USD Million (2017-2022)
  • Table 16. South America Carrier Screening, by Country USD Million (2017-2022)
  • Table 17. South America Carrier Screening, by Type USD Million (2017-2022)
  • Table 18. South America Carrier Screening, by Application USD Million (2017-2022)
  • Table 19. South America Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 20. South America Carrier Screening, by Solution USD Million (2017-2022)
  • Table 21. Brazil Carrier Screening, by Type USD Million (2017-2022)
  • Table 22. Brazil Carrier Screening, by Application USD Million (2017-2022)
  • Table 23. Brazil Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 24. Brazil Carrier Screening, by Solution USD Million (2017-2022)
  • Table 25. Argentina Carrier Screening, by Type USD Million (2017-2022)
  • Table 26. Argentina Carrier Screening, by Application USD Million (2017-2022)
  • Table 27. Argentina Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 28. Argentina Carrier Screening, by Solution USD Million (2017-2022)
  • Table 29. Rest of South America Carrier Screening, by Type USD Million (2017-2022)
  • Table 30. Rest of South America Carrier Screening, by Application USD Million (2017-2022)
  • Table 31. Rest of South America Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 32. Rest of South America Carrier Screening, by Solution USD Million (2017-2022)
  • Table 33. Asia Pacific Carrier Screening, by Country USD Million (2017-2022)
  • Table 34. Asia Pacific Carrier Screening, by Type USD Million (2017-2022)
  • Table 35. Asia Pacific Carrier Screening, by Application USD Million (2017-2022)
  • Table 36. Asia Pacific Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 37. Asia Pacific Carrier Screening, by Solution USD Million (2017-2022)
  • Table 38. China Carrier Screening, by Type USD Million (2017-2022)
  • Table 39. China Carrier Screening, by Application USD Million (2017-2022)
  • Table 40. China Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 41. China Carrier Screening, by Solution USD Million (2017-2022)
  • Table 42. Japan Carrier Screening, by Type USD Million (2017-2022)
  • Table 43. Japan Carrier Screening, by Application USD Million (2017-2022)
  • Table 44. Japan Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 45. Japan Carrier Screening, by Solution USD Million (2017-2022)
  • Table 46. India Carrier Screening, by Type USD Million (2017-2022)
  • Table 47. India Carrier Screening, by Application USD Million (2017-2022)
  • Table 48. India Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 49. India Carrier Screening, by Solution USD Million (2017-2022)
  • Table 50. South Korea Carrier Screening, by Type USD Million (2017-2022)
  • Table 51. South Korea Carrier Screening, by Application USD Million (2017-2022)
  • Table 52. South Korea Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 53. South Korea Carrier Screening, by Solution USD Million (2017-2022)
  • Table 54. Taiwan Carrier Screening, by Type USD Million (2017-2022)
  • Table 55. Taiwan Carrier Screening, by Application USD Million (2017-2022)
  • Table 56. Taiwan Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 57. Taiwan Carrier Screening, by Solution USD Million (2017-2022)
  • Table 58. Australia Carrier Screening, by Type USD Million (2017-2022)
  • Table 59. Australia Carrier Screening, by Application USD Million (2017-2022)
  • Table 60. Australia Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 61. Australia Carrier Screening, by Solution USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Carrier Screening, by Type USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Carrier Screening, by Application USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Carrier Screening, by Solution USD Million (2017-2022)
  • Table 66. Europe Carrier Screening, by Country USD Million (2017-2022)
  • Table 67. Europe Carrier Screening, by Type USD Million (2017-2022)
  • Table 68. Europe Carrier Screening, by Application USD Million (2017-2022)
  • Table 69. Europe Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 70. Europe Carrier Screening, by Solution USD Million (2017-2022)
  • Table 71. Germany Carrier Screening, by Type USD Million (2017-2022)
  • Table 72. Germany Carrier Screening, by Application USD Million (2017-2022)
  • Table 73. Germany Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 74. Germany Carrier Screening, by Solution USD Million (2017-2022)
  • Table 75. France Carrier Screening, by Type USD Million (2017-2022)
  • Table 76. France Carrier Screening, by Application USD Million (2017-2022)
  • Table 77. France Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 78. France Carrier Screening, by Solution USD Million (2017-2022)
  • Table 79. Italy Carrier Screening, by Type USD Million (2017-2022)
  • Table 80. Italy Carrier Screening, by Application USD Million (2017-2022)
  • Table 81. Italy Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 82. Italy Carrier Screening, by Solution USD Million (2017-2022)
  • Table 83. United Kingdom Carrier Screening, by Type USD Million (2017-2022)
  • Table 84. United Kingdom Carrier Screening, by Application USD Million (2017-2022)
  • Table 85. United Kingdom Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 86. United Kingdom Carrier Screening, by Solution USD Million (2017-2022)
  • Table 87. Netherlands Carrier Screening, by Type USD Million (2017-2022)
  • Table 88. Netherlands Carrier Screening, by Application USD Million (2017-2022)
  • Table 89. Netherlands Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 90. Netherlands Carrier Screening, by Solution USD Million (2017-2022)
  • Table 91. Rest of Europe Carrier Screening, by Type USD Million (2017-2022)
  • Table 92. Rest of Europe Carrier Screening, by Application USD Million (2017-2022)
  • Table 93. Rest of Europe Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 94. Rest of Europe Carrier Screening, by Solution USD Million (2017-2022)
  • Table 95. MEA Carrier Screening, by Country USD Million (2017-2022)
  • Table 96. MEA Carrier Screening, by Type USD Million (2017-2022)
  • Table 97. MEA Carrier Screening, by Application USD Million (2017-2022)
  • Table 98. MEA Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 99. MEA Carrier Screening, by Solution USD Million (2017-2022)
  • Table 100. Middle East Carrier Screening, by Type USD Million (2017-2022)
  • Table 101. Middle East Carrier Screening, by Application USD Million (2017-2022)
  • Table 102. Middle East Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 103. Middle East Carrier Screening, by Solution USD Million (2017-2022)
  • Table 104. Africa Carrier Screening, by Type USD Million (2017-2022)
  • Table 105. Africa Carrier Screening, by Application USD Million (2017-2022)
  • Table 106. Africa Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 107. Africa Carrier Screening, by Solution USD Million (2017-2022)
  • Table 108. North America Carrier Screening, by Country USD Million (2017-2022)
  • Table 109. North America Carrier Screening, by Type USD Million (2017-2022)
  • Table 110. North America Carrier Screening, by Application USD Million (2017-2022)
  • Table 111. North America Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 112. North America Carrier Screening, by Solution USD Million (2017-2022)
  • Table 113. United States Carrier Screening, by Type USD Million (2017-2022)
  • Table 114. United States Carrier Screening, by Application USD Million (2017-2022)
  • Table 115. United States Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 116. United States Carrier Screening, by Solution USD Million (2017-2022)
  • Table 117. Canada Carrier Screening, by Type USD Million (2017-2022)
  • Table 118. Canada Carrier Screening, by Application USD Million (2017-2022)
  • Table 119. Canada Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 120. Canada Carrier Screening, by Solution USD Million (2017-2022)
  • Table 121. Mexico Carrier Screening, by Type USD Million (2017-2022)
  • Table 122. Mexico Carrier Screening, by Application USD Million (2017-2022)
  • Table 123. Mexico Carrier Screening, by Medical Conditions USD Million (2017-2022)
  • Table 124. Mexico Carrier Screening, by Solution USD Million (2017-2022)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Carrier Screening: by Type(USD Million)
  • Table 137. Carrier Screening Molecular Screening Test , by Region USD Million (2023-2028)
  • Table 138. Carrier Screening Biochemical Screening Test , by Region USD Million (2023-2028)
  • Table 139. Carrier Screening: by Application(USD Million)
  • Table 140. Carrier Screening Hospitals , by Region USD Million (2023-2028)
  • Table 141. Carrier Screening Clinics , by Region USD Million (2023-2028)
  • Table 142. Carrier Screening Ambulatory Surgical Centers , by Region USD Million (2023-2028)
  • Table 143. Carrier Screening: by Medical Conditions(USD Million)
  • Table 144. Carrier Screening Fragile x syndrome , by Region USD Million (2023-2028)
  • Table 145. Carrier Screening Spinal muscular atrophy , by Region USD Million (2023-2028)
  • Table 146. Carrier Screening Alpha thalassemia , by Region USD Million (2023-2028)
  • Table 147. Carrier Screening Cystic fibrosis , by Region USD Million (2023-2028)
  • Table 148. Carrier Screening: by Solution(USD Million)
  • Table 149. Carrier Screening Service , by Region USD Million (2023-2028)
  • Table 150. Carrier Screening Product , by Region USD Million (2023-2028)
  • Table 151. South America Carrier Screening, by Country USD Million (2023-2028)
  • Table 152. South America Carrier Screening, by Type USD Million (2023-2028)
  • Table 153. South America Carrier Screening, by Application USD Million (2023-2028)
  • Table 154. South America Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 155. South America Carrier Screening, by Solution USD Million (2023-2028)
  • Table 156. Brazil Carrier Screening, by Type USD Million (2023-2028)
  • Table 157. Brazil Carrier Screening, by Application USD Million (2023-2028)
  • Table 158. Brazil Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 159. Brazil Carrier Screening, by Solution USD Million (2023-2028)
  • Table 160. Argentina Carrier Screening, by Type USD Million (2023-2028)
  • Table 161. Argentina Carrier Screening, by Application USD Million (2023-2028)
  • Table 162. Argentina Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 163. Argentina Carrier Screening, by Solution USD Million (2023-2028)
  • Table 164. Rest of South America Carrier Screening, by Type USD Million (2023-2028)
  • Table 165. Rest of South America Carrier Screening, by Application USD Million (2023-2028)
  • Table 166. Rest of South America Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 167. Rest of South America Carrier Screening, by Solution USD Million (2023-2028)
  • Table 168. Asia Pacific Carrier Screening, by Country USD Million (2023-2028)
  • Table 169. Asia Pacific Carrier Screening, by Type USD Million (2023-2028)
  • Table 170. Asia Pacific Carrier Screening, by Application USD Million (2023-2028)
  • Table 171. Asia Pacific Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 172. Asia Pacific Carrier Screening, by Solution USD Million (2023-2028)
  • Table 173. China Carrier Screening, by Type USD Million (2023-2028)
  • Table 174. China Carrier Screening, by Application USD Million (2023-2028)
  • Table 175. China Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 176. China Carrier Screening, by Solution USD Million (2023-2028)
  • Table 177. Japan Carrier Screening, by Type USD Million (2023-2028)
  • Table 178. Japan Carrier Screening, by Application USD Million (2023-2028)
  • Table 179. Japan Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 180. Japan Carrier Screening, by Solution USD Million (2023-2028)
  • Table 181. India Carrier Screening, by Type USD Million (2023-2028)
  • Table 182. India Carrier Screening, by Application USD Million (2023-2028)
  • Table 183. India Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 184. India Carrier Screening, by Solution USD Million (2023-2028)
  • Table 185. South Korea Carrier Screening, by Type USD Million (2023-2028)
  • Table 186. South Korea Carrier Screening, by Application USD Million (2023-2028)
  • Table 187. South Korea Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 188. South Korea Carrier Screening, by Solution USD Million (2023-2028)
  • Table 189. Taiwan Carrier Screening, by Type USD Million (2023-2028)
  • Table 190. Taiwan Carrier Screening, by Application USD Million (2023-2028)
  • Table 191. Taiwan Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 192. Taiwan Carrier Screening, by Solution USD Million (2023-2028)
  • Table 193. Australia Carrier Screening, by Type USD Million (2023-2028)
  • Table 194. Australia Carrier Screening, by Application USD Million (2023-2028)
  • Table 195. Australia Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 196. Australia Carrier Screening, by Solution USD Million (2023-2028)
  • Table 197. Rest of Asia-Pacific Carrier Screening, by Type USD Million (2023-2028)
  • Table 198. Rest of Asia-Pacific Carrier Screening, by Application USD Million (2023-2028)
  • Table 199. Rest of Asia-Pacific Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 200. Rest of Asia-Pacific Carrier Screening, by Solution USD Million (2023-2028)
  • Table 201. Europe Carrier Screening, by Country USD Million (2023-2028)
  • Table 202. Europe Carrier Screening, by Type USD Million (2023-2028)
  • Table 203. Europe Carrier Screening, by Application USD Million (2023-2028)
  • Table 204. Europe Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 205. Europe Carrier Screening, by Solution USD Million (2023-2028)
  • Table 206. Germany Carrier Screening, by Type USD Million (2023-2028)
  • Table 207. Germany Carrier Screening, by Application USD Million (2023-2028)
  • Table 208. Germany Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 209. Germany Carrier Screening, by Solution USD Million (2023-2028)
  • Table 210. France Carrier Screening, by Type USD Million (2023-2028)
  • Table 211. France Carrier Screening, by Application USD Million (2023-2028)
  • Table 212. France Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 213. France Carrier Screening, by Solution USD Million (2023-2028)
  • Table 214. Italy Carrier Screening, by Type USD Million (2023-2028)
  • Table 215. Italy Carrier Screening, by Application USD Million (2023-2028)
  • Table 216. Italy Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 217. Italy Carrier Screening, by Solution USD Million (2023-2028)
  • Table 218. United Kingdom Carrier Screening, by Type USD Million (2023-2028)
  • Table 219. United Kingdom Carrier Screening, by Application USD Million (2023-2028)
  • Table 220. United Kingdom Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 221. United Kingdom Carrier Screening, by Solution USD Million (2023-2028)
  • Table 222. Netherlands Carrier Screening, by Type USD Million (2023-2028)
  • Table 223. Netherlands Carrier Screening, by Application USD Million (2023-2028)
  • Table 224. Netherlands Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 225. Netherlands Carrier Screening, by Solution USD Million (2023-2028)
  • Table 226. Rest of Europe Carrier Screening, by Type USD Million (2023-2028)
  • Table 227. Rest of Europe Carrier Screening, by Application USD Million (2023-2028)
  • Table 228. Rest of Europe Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 229. Rest of Europe Carrier Screening, by Solution USD Million (2023-2028)
  • Table 230. MEA Carrier Screening, by Country USD Million (2023-2028)
  • Table 231. MEA Carrier Screening, by Type USD Million (2023-2028)
  • Table 232. MEA Carrier Screening, by Application USD Million (2023-2028)
  • Table 233. MEA Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 234. MEA Carrier Screening, by Solution USD Million (2023-2028)
  • Table 235. Middle East Carrier Screening, by Type USD Million (2023-2028)
  • Table 236. Middle East Carrier Screening, by Application USD Million (2023-2028)
  • Table 237. Middle East Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 238. Middle East Carrier Screening, by Solution USD Million (2023-2028)
  • Table 239. Africa Carrier Screening, by Type USD Million (2023-2028)
  • Table 240. Africa Carrier Screening, by Application USD Million (2023-2028)
  • Table 241. Africa Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 242. Africa Carrier Screening, by Solution USD Million (2023-2028)
  • Table 243. North America Carrier Screening, by Country USD Million (2023-2028)
  • Table 244. North America Carrier Screening, by Type USD Million (2023-2028)
  • Table 245. North America Carrier Screening, by Application USD Million (2023-2028)
  • Table 246. North America Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 247. North America Carrier Screening, by Solution USD Million (2023-2028)
  • Table 248. United States Carrier Screening, by Type USD Million (2023-2028)
  • Table 249. United States Carrier Screening, by Application USD Million (2023-2028)
  • Table 250. United States Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 251. United States Carrier Screening, by Solution USD Million (2023-2028)
  • Table 252. Canada Carrier Screening, by Type USD Million (2023-2028)
  • Table 253. Canada Carrier Screening, by Application USD Million (2023-2028)
  • Table 254. Canada Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 255. Canada Carrier Screening, by Solution USD Million (2023-2028)
  • Table 256. Mexico Carrier Screening, by Type USD Million (2023-2028)
  • Table 257. Mexico Carrier Screening, by Application USD Million (2023-2028)
  • Table 258. Mexico Carrier Screening, by Medical Conditions USD Million (2023-2028)
  • Table 259. Mexico Carrier Screening, by Solution USD Million (2023-2028)
  • Table 260. Research Programs/Design for This Report
  • Table 261. Key Data Information from Secondary Sources
  • Table 262. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Carrier Screening: by Type USD Million (2017-2022)
  • Figure 5. Global Carrier Screening: by Application USD Million (2017-2022)
  • Figure 6. Global Carrier Screening: by Medical Conditions USD Million (2017-2022)
  • Figure 7. Global Carrier Screening: by Solution USD Million (2017-2022)
  • Figure 8. South America Carrier Screening Share (%), by Country
  • Figure 9. Asia Pacific Carrier Screening Share (%), by Country
  • Figure 10. Europe Carrier Screening Share (%), by Country
  • Figure 11. MEA Carrier Screening Share (%), by Country
  • Figure 12. North America Carrier Screening Share (%), by Country
  • Figure 13. Global Carrier Screening share by Players 2022 (%)
  • Figure 14. Global Carrier Screening share by Players (Top 3) 2022(%)
  • Figure 15. Global Carrier Screening share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 19. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 21. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 22. Thermo Fisher Scientific (United States) Revenue: by Geography 2022
  • Figure 23. 23andMe (United States) Revenue, Net Income and Gross profit
  • Figure 24. 23andMe (United States) Revenue: by Geography 2022
  • Figure 25. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Danaher Corporation (United States) Revenue: by Geography 2022
  • Figure 27. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 28. QIAGEN (Germany) Revenue: by Geography 2022
  • Figure 29. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Illumina, Inc. (United States) Revenue: by Geography 2022
  • Figure 31. Luminex Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Luminex Corporation (United States) Revenue: by Geography 2022
  • Figure 33. LabCorp (United States) Revenue, Net Income and Gross profit
  • Figure 34. LabCorp (United States) Revenue: by Geography 2022
  • Figure 35. Myriad Genetics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Myriad Genetics, Inc. (United States) Revenue: by Geography 2022
  • Figure 37. Autogenomics (United States) Revenue, Net Income and Gross profit
  • Figure 38. Autogenomics (United States) Revenue: by Geography 2022
  • Figure 39. Global Carrier Screening: by Type USD Million (2023-2028)
  • Figure 40. Global Carrier Screening: by Application USD Million (2023-2028)
  • Figure 41. Global Carrier Screening: by Medical Conditions USD Million (2023-2028)
  • Figure 42. Global Carrier Screening: by Solution USD Million (2023-2028)
  • Figure 43. South America Carrier Screening Share (%), by Country
  • Figure 44. Asia Pacific Carrier Screening Share (%), by Country
  • Figure 45. Europe Carrier Screening Share (%), by Country
  • Figure 46. MEA Carrier Screening Share (%), by Country
  • Figure 47. North America Carrier Screening Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Roche Holding AG (Switzerland)
  • Thermo Fisher Scientific (United States)
  • 23andMe (United States)
  • Danaher Corporation (United States)
  • QIAGEN (Germany)
  • Illumina, Inc. (United States)
  • Luminex Corporation (United States)
  • LabCorp (United States)
  • Myriad Genetics, Inc. (United States)
  • Autogenomics (United States)
Select User Access Type

Key Highlights of Report


May 2023 224 Pages 96 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Carrier Screening Market Quantitative research analysis
Global Carrier Screening Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Genetic Disorders " is seen as one of major growth factors of Carrier Screening Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Carrier Screening market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Carrier Screening Market Report?

Have a Query? Click Here

Other Related Reports

Single Cell Multi-Omics Comprehensive Study by Type (Single Cell Genomics, Single Cell Proteomics, Single Cell Transcriptomics, Single Cell Metabolomics), Application (Oncology, Cell Biology, Neurolo...
$ 3750
Cell Therapy Technology Comprehensive Study by Type (Consumables, Equipment {Cell Processing Equipment, Single-Use Equipment and Other}, Systems and Software), Process (Cell Processing, Cell Preserva...
$ 3650
Micro Algae Paste for Aquaculture Comprehensive Study by Contents (Omega-3 Fatty Acid, Omega-6 Fatty Acid), Hatcheries Applications (Marine Fish, Shrimp, Milkfish, Others (Shellfish, Tilapia)), Paste...
$ 3650
Cultured Meat Comprehensive Study by Type (Poultry, Pork, Beef, Duck), Application (Nuggets, Burgers, Meatballs, Sausages, Hot dogs, Others (include pet food and foie gras)), Distribution Channel (On...
$ 3500
Glycan Analysis Comprehensive Study by Analysis (Mass Spectrometry (MS), High-Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Isoelectric Focusing (IEF) Polyacrylamide Gel (...
$ 3450
Biomedical Nanotechnology Comprehensive Study by Application (Diagnostics, Sensing, Drugs, Prostheses and Implants, Others), Product (Treatment, Nanomedicine (Nanosensors), Agricultural Technology, G...
$ 3450